Xuefu-Zhuyu Capsule for the Treatment of “Qizhi Xueyu Zheng” (Qi Stagnation and Blood Stasis Syndrome)

Overview

"Xuefu-Zhuyu capsule" (XFZY) is made from a classic Fangji "Xuefu-Zhuyu Decoction" in an ancient Chinese medical book "Yi Lin Gai Cuo" by Chinese physician Wang Qingren, which is the most representative formula for the treatment of "Qizhi-Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome). XFZY concludes 11 kinds of Chinese herbs: Danggui(Angelica sinensis), Honghua(Safflower Flower), Chishao(Paeoniae Radix Rubra), Shengdihuang(Radix Rehmanniae), Taoren(Peach Seed), Zhike(Fructus Aurantii), Jugeng(Platycodon grandiflorum), Chuanxiong(Rhizome of Chuanxiong), Chaihu(Radix Bupleuri), Chuanniuxi(Cyathula Officinalis),Gancao(liquorice).It is mainly used to treat "Qizhi-Xueyu Zheng", which includes the symptoms such as different types of pain, irritability or depression, insomnia, chest tightness, dark skin, lumps or masses in vitro or in vivo, petechiae on the tongue, and dark purple tongue. The purpose of the trial is to evaluate the efficacy and safety of XFZY in treating "Qizhi-Xueyu Zheng", and investigate the most suitable diseases of XFZY.

Full Title of Study: “The Efficacy and Safety of Xuefu Zhuyu Capsule in Treating “Qizhi Xueyu Zheng” (Qi Stagnation and Blood Stasis Syndrome): a Randomized, Double-blind, Placebo-controlled, Adaptive Enrichment, Multicenter Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 31, 2021

Interventions

  • Drug: Xuefu-Zhuyu Capsule
    • treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
  • Drug: placebo
    • treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
  • Other: conventional therapy
    • conventional therapy will be given according to the suffering diseases including stable coronary heart disease, chronic insomnia, headache, endometriosis.

Arms, Groups and Cohorts

  • Experimental: XFZY group
    • 2.4g (6 capsules) three times daily for 12 weeks
  • Placebo Comparator: Control group
    • 2.4g (6 capsules) three times daily for 12 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline the Chinese Medicine patient-reported-outcome scale in patients with Qizhi-Xueyu-Zheng (Qizhi-Xueyu-Zheng PRO Scale)
    • Time Frame: at 12 Week
    • The Qizhi-Xueyu-Zheng PRO Scale is uesd to access the quality of life on the physical and mental health for the patients with Qizhi Xueyu Zheng. The higher score of this PRO scale indicates higher quality of life. Compared with the baseline, if the improvement of the PRO sacle is more than 30% after treatment, it indicates the effectiveness of the drug. s

Secondary Measures

  • The single symptom and sign scale of Qizhi Xueyu Zheng
    • Time Frame: Baseline,4,8,12 Week
    • According to the degree of symptoms and signs, the score will be assigned as follows: no = 0; mild = 1; moderate = 2; or severe = 3.
  • The pain scale Qizhi Xueyu Zheng
    • Time Frame: Baseline,4,8,12 Week
    • The total score includes a visual analogue scale pain index and the score of degree, duration, and frequency of pain. The location of the pain will be recorded independently. The total score ranges from 0 to 19, higher score indicating severer pain.
  • Self-rating anxiety scale (SAS)
    • Time Frame: Baseline,4,8,12 Week
    • The SAS scale consists of 20 items each which were scored from 1 to 4. The final score was calculated as the summation of all of the items which was then multiplied by a factor of 1.25. The score ranged from 50-59 indicates mild anxiety;The score from 60-69 indicates moderate anxiety;The score from 60-69 indicates severe anxiety.
  • Self-rating depression scale (SDS)
    • Time Frame: Baseline,4,8,12 Week
    • The SDS scale consists of 20 items each which were scored from 1 to 4. The final score was calculated as the summation of all of the items which was then multiplied by a factor of 1.25. The score ranged from 50-59 indicates mild depression;The score from 60-69 indicates moderate depression;The score from 60-69 indicates severe depression.
  • SF-36 Quality of Life Scale
    • Time Frame: Baseline,4,8,12 Week
    • SF-36 Quality of Life Scale is used to assess the health-related quality of life of patients, which is a multi-purpose, short-form health survey with 36 items. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary scores and a preference-based health utility index. The SF-36 consists of items: assessing physical functioning (PF-10 items),social functioning (SF-2 items), role limitation due to physical health (RP-4 items),bodily pain (BP-2 items),mental health (MH-5 items),role limitations due to emotional health (RE-3 items),vitality (VT-4 items);general health perceptions (GH-5 items);reported health transition (1 item).
  • Level of the 5-hydroxytryptamine(5-HT)
    • Time Frame: Baseline,4,8,12 Week
  • Level of the high-sensitivity C-reactive protein
    • Time Frame: Baseline,4,8,12 Week

Participating in This Clinical Trial

Inclusion Criteria

  • Meet the diagnostic criteria of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome). – Meet the diagnostic criteria of stable coronary heart disease, chronic insomnia, headache (Migraine without Aura and Tension-Type Headache ), or endometriosis, among which: – the score of angina pectoris frequency domain in SAQ ≤ 80 points in the patients with stable coronary heart disease; – Pittsburgh sleep quality index> 10 points in patients with chronic insomnia; – Patients with migraine without aura have 3 or more attacks per month within 3 months before enrollment; – In patients with tension-Type headache, within 3 months before enrollment, the number of attack days per month is ≥ 2 days; – The VAS score of the pain ≥ 40 points in patients with endometriosis; – Patients with endometriosis diagnosed with any type of confirmed pathological reports(previous diagnosis is also possible). – Patients were ≥18 and ≤75 years of age. – Voluntarily provided written informed consent. Exclusion Criteria:

  • Patients with acute myocardial infarction, rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia and other severe arrhythmias and severe cardiac and pulmonary insufficiency in the past 3 months – Patients with acute cerebrovascular disease such as cerebral infarction and cerebral hemorrhage in the past 3 months; – Those with poorly controlled hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg after treatment); – Patients with aortic dissection; – Patients with abnormal liver and kidney function indicators (ALT, AST are 1.5 times greater than the upper limit of normal value, and Scr is greater than the upper limit of normal value); – SAS≥70 points; – SDS≥73 points; – VAS≥80 points; – Patients with severe primary heart, brain, liver, kidney, and hematopoietic diseases; – Women during pregnancy and lactation; – Those with cognitive impairment, consciousness impairment or mental illness, who cannot communicate normally; – People with allergies, or those who are known to be allergic to the trial drug (including its components); – Surgery(including intervention, radio frequency, etc.) during the past 4 weeks; – Those with bleeding tendency; – Those who suspect or have a history of alcohol or drug abuse; – Participation in another trial in the past 1 month; – Other circumstances judged by the researcher to be unsuitable for participation in the trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Zhong Wang
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Zhong Wang, Professor – China Academy of Chinese Medical Sciences
  • Overall Official(s)
    • Zhong Wang, M.D., Study Director, Institute of Basic Chinese Medical Sciences, China Academy of Chinese Medical Sciences
    • Qing-Quan Liu, Prof., Principal Investigator, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
  • Overall Contact(s)
    • Jun Liu, PhD., 15010529005, franlj1104@aliyun.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.